Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13123
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPietersz, Geoffrey Aen
dc.contributor.authorKrauer, K Gen
dc.date.accessioned2015-05-16T02:54:29Z
dc.date.available2015-05-16T02:54:29Z
dc.date.issued1994-05-16en
dc.identifier.citationJournal of Drug Targeting; 2(3): 183-215en
dc.identifier.govdoc7812691en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/13123en
dc.description.abstractThe advent of monoclonal antibodies has revitalised the concept of magic bullets and various agents (eg. drugs, toxins and isotopes) have been conjugated to monoclonal antibodies for selective delivery to tumours. Preclinical studies in mouse tumour models have been impressive and have lead to several clinical trials. These phase I trials have been less impressive. However, keeping in mind the aim of Phase I trials, the safety of using these conjugates in humans have been established. Several, major problems still remain to be overcome before these agents may be useful for the treatment of cancer. These problems stem from the nature of tumour vasculature, cytotoxic activity of the moiety linked to antibody and the targeted tumour antigen expressed on the cell surface. This review will deal with these various aspects described above and possible approaches to overcome these obstacles with a definite bias towards drug-monoclonal antibody conjugates. However, these concepts are equally applicable for improved targeting of other agents.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherAntibodies, Monoclonal.immunology.metabolism.therapeutic useen
dc.subject.otherAntibodies, Neoplasm.genetics.metabolismen
dc.subject.otherAntibody Specificityen
dc.subject.otherAntigen-Antibody Reactionsen
dc.subject.otherAntigens, Neoplasm.genetics.metabolismen
dc.subject.otherAntineoplastic Agents.metabolism.therapeutic useen
dc.subject.otherDisease Models, Animalen
dc.subject.otherGene Expression Regulation, Neoplasticen
dc.subject.otherHumansen
dc.subject.otherImmunoconjugates.adverse effects.genetics.therapeutic use.toxicityen
dc.subject.otherMiceen
dc.subject.otherNeoplasms.drug therapyen
dc.titleAntibody-targeted drugs for the therapy of cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of drug targetingen
dc.identifier.affiliationAustin Research Institute, Austin Hospital, Heidelberg Victoria, Australiaen
dc.identifier.doi10.3109/10611869408996804en
dc.description.pages183-215en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/7812691en
dc.type.austinJournal Articleen
item.languageiso639-1en-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Jun 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.